Skip to content

Autonomic Mechanisms of Sleep-dependent Memory Consolidation

Autonomic Mechanisms of Sleep-dependent Memory Consolidation

Status
Terminated
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04021797
Acronym
MemS
Enrollment
12
Registered
2019-07-16
Start date
2019-10-15
Completion date
2020-03-15
Last updated
2026-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Memory, Sleep

Brief summary

The goal of the proposed project is to identify the impact vagal activity during sleep for memory formation. Nearly 100 years of research contends that sleep plays a critical role in memory consolidation (i.e. the transformation of recent experiences into stable, long-term memories), yet much of this literature has focused on the central nervous system and technologies like electroencephalography (EEG) to unpack neural correlates involved in memory processing. Sleep is also a unique period of autonomic variation and an expansive literature has indicated the critical importance of the autonomic nervous system for memory formation. This project would be amongst the first to examine the autonomic nervous system during sleep as a critical, causal pathway linking sleep to memory processing. The investigators will assess the impact of non-invasive, transcutaneous vagal nerve stimulation on sleep and post-sleep memory performance. Autonomic physiology, including electrocardiography and impedance cardiography, will be gathered at baseline, before the memory task and continuously during sleep to examine vagal tone (i.e. heart rate variability) and sympathetic activation (i.e. pre-ejection period) in response to both active and sham stimulation conditions. Polysomnography will also be gathered during the nap to examine sleep architecture. The proposed research will address a critical gap in the literature by: 1) examining the causal role of the ANS for memory functioning in humans, 2) extending the current understanding of sleep's impact on memory processing, and 3) set the groundwork for novel, sleep-based interventions with the goal of improving cognitive health.

Detailed description

Poor sleep is associated with significant cognitive health decline. Recently, sleep disturbances have emerged as notable predictive and exacerbating factors in the onset and development of neurodegenerative disease. Decades of research have implicated that sleep plays a critical role in memory consolidation (i.e. the transformation of recent experiences into stable, long-term memories), the decline of which is critical in the early stages of dementia. This literature affords that sleep, a period of reduced external interference, provides an optimal window for memory consolidation and that electrophysiological features that emerge during sleep are integrally involved in the consolidation process. Most of this literature has focused on the central nervous system and technologies like electroencephalography (EEG) to unpack neural correlates involved in memory processing. However, little impact from this work has translated into practical treatments and recent reviews of the literature question these sleep - memory associations. This lack of clarity suggests that there may be other factors critical to our understanding of sleep-dependent memory consolidation that have not been given due consideration. This proposal suggests that the autonomic nervous system (ANS) during sleep may reflect a critical, though understudied, pathway linking sleep and memory. An expansive body of research has supported the role of the ANS for memory formation. Rodent studies have found that the storage of new information in memory is either enriched or impaired following learning acquisition by directly modifying peripheral activity through the vagus nerve. The vagus nerve is responsible for communicating information about peripheral excitation and arousal via projections to the brainstem, which then projects to memory-related areas including the amygdala complex, hippocampus, and prefrontal cortex. Indeed, in humans, researchers have demonstrated that direct stimulation of the vagus nerve, via surgical implants, can enhance declarative memory in epileptic patients and in patients with Alzheimer's Disease. Recently, in a sample of healthy older adults, non-invasive (transcutaneous) vagal nerve stimulation during wake boosted memory for face-name associations. Importantly, previous research has demonstrated the predominance of parasympathetic/vagal activity during sleep, particularly during slow wave sleep, which has received critical attention for its causal role in declarative memory consolidation. More so, the PI's work has shown that sleep acts as a regulatory influence over vagal activity and that vagally-mediated activity during sleep can predict post-sleep memory improvement. Yet, few investigations have examined the causal impact of vagal activity during sleep for memory outcomes, which is the central aim of this application. In this project, the investigators will utilize a within-subject, sham-controlled, counterbalanced design to determine the impact of active (inside of left ear) vs. sham (left earlobe) transcutaneous vagal nerve stimulation (tVNS) on: 1) sleep architecture, 2) autonomic activity during sleep, and 3) memory performance post-sleep. To this end, the investigators will utilize a daytime nap protocol, a common methodological tool used to assess the role of sleep for cognition. A nap approach allows for strict circadian-control of cognition and provides for an examination of tVNS's impact on a full cycle of sleep that includes both NREM and REM stages. The researchers will assess declarative memory performance, using a word-pair associates task, before and after the nap period for both the active and sham stimulation conditions. Autonomic physiology, including electrocardiography and impedance cardiography, will be gathered at baseline before the word-pairs task and continuously during sleep to examine vagal tone (i.e. heart rate variability) and sympathetic activation (i.e. pre-ejection period) in response to both the active and sham stimulation conditions. Polysomnography will also be gathered during the nap to examine sleep architecture.

Interventions

The transcutaneous stimulator engages the cymba conchae in the left inner ear, compared to the left earlobe in the sham stimulation condition.

Sponsors

University of California, San Francisco
Lead SponsorOTHER
National Center for Advancing Translational Sciences (NCATS)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Outcomes Assessor)

Masking description

Participant's will not be aware which configuration represents the sham vs active stimulation condition. Data analyses will be conducted blind to sham or active stimulation.

Intervention model description

We will employ a within-subjects, crossover, sham-controlled design. Each participant will be exposed to both active and sham conditions over two visits (5-days apart).

Eligibility

Sex/Gender
ALL
Age
18 Years to 64 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy, adult volunteers between the ages of 18-64. * English speaking * Self-reported napping

Exclusion criteria

* Aged greater than 64 years * Lack of adherence to sleep/wake schedule of at least 7 hours a night for 5-days prior to study and during study timeline. * Body mass index of 35 or above * Presence of any clinical sleep disorder, including insomnia and obstructive sleep apnea (OSA) * Presence of medical or psychiatric condition that is likely to affect sleep/wake function or cardiovascular functioning, including doctor diagnosed arrhythmia, bradycardia, hypertension, congestive heart failure, major depression, bipolar disorder, post-traumatic stress disorder. * Medication use that is likely to affect sleep/wake function or cardiovascular functioning, including antidepressants, anxiolytic or soporific medication, and beta-blockers. * Pregnancy * Epilepsy * head trauma * alcoholism * migraines * metal pieces in the body (may confound tVNS delivery) * history of substance abuse

Design outcomes

Primary

MeasureTime frameDescription
Delayed Memory Percent Accuracymeasured on day 6 and on day 12In this task, subjects will be visually presented with 40 word pairs (e.g. table-hot) on a computer screen. During encoding, each word pair will be presented 3x for 4000ms. At test, participants are presented with one of the word pairs and prompted to type, using the keyboard, the previously matched word. Performance will be calculated as percent accuracy at each retrieval test (# of items correct / 20).

Secondary

MeasureTime frameDescription
Minutes in Slow Wave Sleepmeasured on day 6 and on day 12Sleep staging was performed in 30-second epochs on the recorded polysomnography. Total time spent in each sleep stage was computed across the entire 90-minute nap opportunity. Slow wave sleep stages were aggregated and the total minutes spent in that sleep stage are reported.
Delta EEG Powermeasured on day 6 and on day 12Absolute band power (µV²) was calculated in the delta frequency band (0.5-3.5 Hz) within Stage N2 and N3 of NREM sleep.
High Frequency Heart Rate Variabilitymeasured on day 6 and on day 12Consecutive, artifact-free periods of uninterrupted sleep were chosen during the nap to study RR, HR, and frequency-domain HRV measurements throughout each sleep stage. Each window lasted for three minutes, and there were no stage shifts or movement artifacts during the 2 minutes that preceded the window or the full three minutes of the window. The absolute spectral power (ms2) in the HF-HRV (0.15-0.40 Hz; ms2) frequency bands is reported.
Sympathetic Activitymeasured on day 6 and on day 12The pre-ejection period was calculated as the time delay in the heart between ventricular electrical activity and the pumping of blood.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORLauren N Whitehurst, PhD

University of California, San Francisco

Participant flow

Pre-assignment details

12 participants signed the informed consent form, and 11 were randomized to the study.

Baseline characteristics

Characteristic
Age, Continuous28 years
STANDARD_DEVIATION 4.09
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
2 Participants
Race (NIH/OMB)
Black or African American
0 Participants
Race (NIH/OMB)
More than one race
1 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
1 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
Race (NIH/OMB)
White
3 Participants
Sex: Female, Male
Female
3 Participants
Sex: Female, Male
Male
3 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
0 / 110 / 11
other
Total, other adverse events
0 / 110 / 11
serious
Total, serious adverse events
0 / 110 / 11

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 16, 2026